Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or ImatinibHo Jae Han, Dennis Dong Hwan Kim, Anthea Travas et al.|Blood|2023Cited by 2
Leptin-Enhanced JAK-STAT Signaling in Acute Myeloid Leukemia-Derived Mesenchymal Stromal Cells and Its Implications for Disease ProgressionMuzaffar Bhatti, Dennis Dong Hwan Kim, Troy Ketela et al.|Blood|2024Cited by 2
Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free RemissionMaría Agustina Perusini, Dennis Dong Hwan Kim, Jaeyoon Kim et al.|Blood|2023Cited by 0
In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid LeukemiaHo Jae Han, Dennis Dong Hwan Kim, Eunju Park et al.|Blood|2023Cited by 0
Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML PatientsMay Chiu, Dennis Dong Hwan Kim, María Agustina Perusini et al.|Blood|2024Cited by 0